We read the article “Volatile versus Total Intravenous Anesthesia for Cancer Prognosis in Patients Having Digestive Cancer Surgery” by Makito et al.1  with great interest. This study is a large clinical retrospective study of more than 190,000 surgical patients with cancer. For further statistical analysis, the authors did a score-matching analysis to compensate for the huge difference in the number of patients who received volatile or intravenous anesthesia. They concluded that there were no significant differences between anesthetic choices on cancer recurrence/survival after surgery. However, we found several limitations in this study which may distort the data analysis. First, various cancer types and surgeries were included in the same analysis; however, it is well known that cancer aggressiveness and malignancy largely differ between cancer types and their origins.2  Second, the subgroup analysis for each type of surgery (presented in table 2 of Makito et al.) did not specify open surgery or laparoscopic surgery. Previous studies have demonstrated in preclinical and clinical settings that surgical trauma/stress and associated systemic inflammation, which often occurs in major open surgeries, promoted cancer progression and malignancy, leading to worse outcomes.3,4  Lastly, there were no data about perioperative steroid and/or nonsteroidal anti-inflammatory drug use; those medications, which are often used during the perioperative period, have been found to improve the clinical outcome in several types of cancers.5  The crosslink between the inflammation and cancer progression after surgery would affect cancer surgical outcomes. It would be great if the authors could elaborate on our concerns for future refined studies wherever possible.

The authors declare no competing interests.

1.
Makito
K
,
Matsui
H
,
Fushimi
K
,
Yasunaga
H
.
Volatile versus total intravenous anesthesia for cancer prognosis in patients having digestive cancer surgery.
Anesthesiology
.
2020
;
133
:
764
73
2.
Bray
F
,
Ferlay
J
,
Soerjomataram
I
,
Siegel
RL
,
Torre
LA
,
Jemal
A
.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin
.
2018
;
68
:
394
424
3.
Krall
JA
,
Reinhardt
F
,
Mercury
OA
,
Pattabiraman
DR
,
Brooks
MW
,
Dougan
M
,
Lambert
AW
,
Bierie
B
,
Ploegh
HL
,
Dougan
SK
,
Weinberg
RA
.
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy.
Sci Transl Med
.
2018
;
10
:
eaan3464
4.
Wu
TC
,
Xu
K
,
Martinek
J
,
Young
RR
,
Banchereau
R
,
George
J
,
Turner
J
,
Kim
KI
,
Zurawski
S
,
Wang
X
,
Blankenship
D
,
Brookes
HM
,
Marches
F
,
Obermoser
G
,
Lavecchio
E
,
Levin
MK
,
Bae
S
,
Chung
CH
,
Smith
JL
,
Cepika
AM
,
Oxley
KL
,
Snipes
GJ
,
Banchereau
J
,
Pascual
V
,
O’Shaughnessy
J
,
Palucka
AK
.
IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer.
Cancer Res
.
2018
;
78
:
5243
58
5.
Huang
WW
,
Zhu
WZ
,
Mu
DL
,
Ji
XQ
,
Nie
XL
,
Li
XY
,
Wang
DX
,
Ma
D
.
Perioperative management may improve long-term survival in patients after lung cancer surgery: A retrospective cohort study.
Anesth Analg
.
2018
;
126
:
1666
74